Document is current
Any future updates will be listed below
-
Authors
Serper, Marina
Evon, Donna M.
Stewart, Paul W.
Lok, Anna S.
Amador, Jipcy
Reeve, Bryce B.
Golin, Carol E.
Fried, Michael W.
Reddy, K. Rajender
Sterling, Richard K.
Sarkar, Souvik
Di Bisceglie, Adrian M.
Lim, Joseph K.
Nelson, David R.
Reau, Nancy
- License Information
-
More Information
Article History
Received: 15 February 2019
Revised: 15 July 2019
Accepted: 23 August 2019
First Online: 28 October 2019
Compliance with Ethical Standards
: Sites obtained local Institutional Review Board (IRB) approval and all participants provided informed consent.
: Donna M. Evon receives research funding from Gilead and Merck (paid to UNC). Michael Fried has received research funding from and served as a consultant for AbbVie, BMS, Gilead, Merck, and TARGET PharmaSolutions. Stock in TARGET PharmaSolutions is held in an independently managed trust. Anna S. Lok has received research support from BMS, Gilead, TARGET PharmaSolutions, AbbVie, and Merck, and served as an advisor for Gilead. Richard K. Sterling has received research support from AbbVie, BMS, Gilead, Merck, and Roche, and served as a consultant for Merck, Bayer, Sa2lix, AbbVie, Gilead, Jansen, ViiV, Baxter, and Pfizer. Joseph K. Lim has received research support (paid to Yale University) and served as a consultant for Bristol-Myers Squibb and Gilead. Nancy Reau has received research funding (paid to Rush) from AbbVie and Intercept and has served as a consultant for Merck, AbbVie, Abbott, and Gilead. Souvik Sarkar served on a Gilead and AbbVie Advisory Board. David R. Nelson has received research grant support from AbbVie, BMS, Gilead, Janssen, and Merck and owns stock in TARGET PharmaSolutions. K. Rajender Reddy is an Ad-Hoc Advisor to Gilead, BMS, Janssen, Merck, and AbbVie and has received research support from Gilead, BMS, Janssen, Merck, and AbbVie (paid to the University of Pennsylvania). Adrian M. Di Bisceglie has received research support from AbbVie, BMS, and Gilead and has served on advisory boards for AbbVie, BMS, Gilead, and Merck. He serves as Chair of the Steering Committee for TARGET HCC, a registry study funded by TARGET PharmaSolutions. Paul Stewart has served as a consultant to TARGET PharmaSolutions. Jipcy Amador served as a biostatistics intern at TARGET PharmaSolutions in 2017. Carol E. Golin, Marina Serper, and Bryce Reeve declare that they have no conflict of interests to disclose.
Free to read: This content has been made available to all.
